Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) highlighted progress across its molecular glue degrader pipeline during a presentation at the Barclays 28th Annual Global Healthcare Conference, with Chief Medical Officer Filip Janku outlining upcoming clinical milestones in inflammation and immunology (I&I) and oncology. Molecular glue degraders and “undruggable” targets Janku described molecular glue degraders as a modality aimed at “drugging undruggable” targets by reshaping the surface of an E3 ligase (such as cereblon) to enable a new protein-to-protein interaction with a disease-causing target protein, leading to its elimination. He contrasted this with heterobifunctional degraders, which include multiple components and require a target-binding element connected via a linker to an E3 ligase-binding element. In his view, heterobifunctionals can be seen as more akin to “redrugging druggable” targets because they still rely on binding to the target in a traditional way. NEK7 degrader MR
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business UpdatesGlobeNewswire
- Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerGlobeNewswire
- Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering [Yahoo! Finance]Yahoo! Finance
GLUE
Sec Filings
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- 3/5/26 - Form 4
- GLUE's page on the SEC website